Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reported Q1 2026 revenues of $72.4M, driven by a 34% increase in Joenja® sales and continued RUCONEST® revenues amid strategic market exits. The company secured pediatric approval for Joenja® in Japan, received a positive CHMP opinion in Europe, and resubmitted its pediatric sNDA in the U.S., positioning for label expansion. Pharming…